RISING TIDE: Robert Bradway, on deck as Amgen’s next CEO, predicts newer products and expanding operations into more countries to bring higher revenue down the road.
MOMENTUM: Positive developments include last year’s purchase of a cancer vaccine developer and moves to protect long-term sales of top seller Enbrel, for psoriasis and rheumatoid arthritis, and anemia treatment Epogen.
MANAGEMENT MOVES: Along with Bradway, Amgen has appointed new heads of commercial operations and research and development. It also plans more share buybacks.
